FDA Approves Enhertu to Treat Gastric and GEJ Adenocarcinomas

Published by W Butcher on

The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a trastuzumab-based regimen.

Read More…

Categories: Uncategorized


Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *